Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 mavorixafor study in WHIM syndrome
NL-OMON58747Phase 3Completed
- Sponsor
- X4 Pharmaceuticals, Inc.
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mavorixafor in WHIM syndrome (WHIM) (3 arms), sponsored by X4 Pharmaceuticals, Inc. Primary endpoints: Time above threshold absolute neutrophil count and Long-term safety and tolerability. Started Jan 2026; status: completed.
02
Drugs
mavorixafor
03
Conditions
WHIM syndrome (WHIM)
Beyond the preview
Go deeper on NL-OMON58747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58747.